P. Foxworthy

发表

Coadministration of a Liver X Receptor Agonist and a Peroxisome Proliferator Activator Receptor-α Agonist in Mice: Effects of Nuclear Receptor Interplay on High-Density Lipoprotein and Triglyceride Metabolism in Vivo

S. Karathanasis, P. Eacho, R. Schmidt, 2004, Journal of Pharmacology and Experimental Therapeutics.

A Chemical Switch Regulates Fibrate Specificity for Peroxisome Proliferator-activated Receptor α (PPARα) VersusLiver X Receptor*

K. Bramlett, W. Chin, J. Mccowan, 2003, The Journal of Biological Chemistry.

Characterization of liver enlargement induced by compound LY171883 in rats.

P. Eacho, W. Johnson, P. Foxworthy, 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Estrogen receptor-mediated repression of human hepatic lipase gene transcription.

P. Eacho, R. Schmidt, P. Foxworthy, 2002, Journal of lipid research.

Synthesis and in vitro biological activity of 4α-(2-propenyl)-5α-cholest-24-en-3α,12α-diol, a 12α-hydroxyl analog of 4α-(2-propenyl)-5α-cholest-24-en-3α-ol: The latter is a potent activator of the low-density lipoprotein receptor promoter

D. Mcclure, P. Eacho, L. Beavers, 1999, Steroids.

Synthesis and in vitro biological activity of 4α-(2-propenyl)-5α-cholest-24-en-3α-ol: A 24,25-dehydro analog of the hypocholesterolemic agent 4α-(2-propenyl)-5α-cholestan-3α-ol

R. W. Harper, D. Mcclure, P. Eacho, 1999, Steroids.

Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation.

M. Rekhter, C. Vlahos, R. Gilmour, 2008, Biochemical and biophysical research communications.

Common Structural Requirements for Peroxisome Proliferation by Tetrazole and Carboxylic Acid‐Containing Compounds

D. Noonan, D. K. Herron, P. Eacho, 1996, Annals of the New York Academy of Sciences.

Cultured hepatocytes for studies of peroxisome proliferation: methods and applications.

P. Eacho, P. Foxworthy, 1994, Journal of pharmacological and toxicological methods.

Effects of chronic treatment with the leukotriene D4-antagonist compound LY171883 on B6C3F1 mice.

A. Bendele, P. Eacho, D. Hoover, 1990, Fundamental and applied toxicology : official journal of the Society of Toxicology.

The effects of peroxisome proliferators on protein abundances in mouse liver.

N. Anderson, P. Eacho, N L Anderson, 1996, Toxicology and applied pharmacology.

Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species.

P. Eacho, W. Johnson, D. Hoover, 1986, Toxicology and applied pharmacology.

Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.

P. Eacho, D. Hoover, P. Foxworthy, 1990, Toxicology and applied pharmacology.

Conditions influencing the induction of peroxisomal beta-oxidation in cultured rat hepatocytes.

P. Eacho, P. Foxworthy, 1986, Toxicology letters.

Changes in hepatic lipid metabolism associated with lipid accumulation and its reversal in rats given the peroxisome proliferator LY171883.

P. Eacho, D. Hoover, P. Foxworthy, 1990, Toxicology and applied pharmacology.

Inhibition of hepatic fatty acid oxidation at carnitine palmitoyltransferase I by the peroxisome proliferator 2-hydroxy-3-propyl-4-[6-(tetrazol-5-yl) hexyloxy]acetophenone.

P. Eacho, P. Foxworthy, 1988, The Biochemical journal.

Effect of the peroxisome proliferator LY171883 on triglyceride accumulation in rats fed a fat-free diet.

P. Eacho, P. Foxworthy, 1991, Biochemical pharmacology.

Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.

E. Su, T. Large, P. Eacho, 2005, Biochemical and biophysical research communications.

Effects of chronic treatment with the leukotriene D4 antagonist compound LY171883 on Fischer 344 rats and rhesus monkeys.

A. Bendele, P. Eacho, D. Hoover, 1990, Fundamental and applied toxicology : official journal of the Society of Toxicology.

Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis*

A. R. Miller, G. Etgen, C. Broderick, 2003, The Journal of Biological Chemistry.

Hepatic peroxisomal fatty acid β-oxidation is regulated by liver X receptor α

Angela M. Siesky, S. Li, M. Michael, 2005 .

Hepatic peroxisomal fatty acid beta-oxidation is regulated by liver X receptor alpha.

Angela M. Siesky, S. Li, M. Michael, 2005, Endocrinology.

Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA.

P. Eacho, P. Foxworthy, 1988, Biochemical and biophysical research communications.

Nafenopin-induced peroxisome proliferation in vitamin A deficient rats.

P. Eacho, V. Meador, P. Foxworthy, 1995, Biochemical pharmacology.

Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: Structure-activity relationships

D. K. Herron, P. Eacho, C. Whitesitt, 1989 .

Genome-wide Screen for Modulation of Hepatic Apolipoprotein A-I (ApoA-I) Secretion

P. Yu, M. Kowala, J. Calley, 2013, The Journal of Biological Chemistry.

Genome-wide Screen for Modulation of Hepatic Apolipoprotein A-I (ApoA-I) Secretion

P. Yu, M. Kowala, J. Calley, 2013, The Journal of Biological Chemistry.